• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Dubai Conference Was Success for Medical Services

Posted on: Wednesday, 15 February 2006, 15:00 CST

EDMONTON, Alberta, Feb. 15 /PRNewswire-FirstCall/ -- Medical Services International Inc. is pleased to announce that the Dubai Medical Conference was a huge success for the Company. The Companies new distributor for the Middle East signed contracts in three Middle East countries totaling 2.1 million kits over an 18 month period starting in September, 2006. These orders for the VScan HIV test kit will generate gross revenues of $4.8 million US over this period.

There was also significant interest shown in the Tuberculosis (TB) and Hepatitis C VScan test kits.

In addition to the contracts from the three countries, our distributor has been contacted by representatives from another 6 countries. Samples have been sent to the appropriate regulatory agencies in these countries for testing to be completed. As soon as Medical Services receives the pictures taken at the conference they will be added to the website.

About VScan

The VScan rapid test kit is a single use, disposable, accurate, cost effective, easy to use test for the screening of HIV 1&2, Tuberculosis (TB), Hepatitis B&C Dengue Fever, West Nile, Syphilis, Malaria and Prostate Cancer. The kits cannot be sold in Canada.

Medical Services International Inc. trades in the United States on the NQB Pinksheets under the symbol "MSITF". For further information, please contact Robert Talbot at (780) 430 6363 or media contact Bill Whitehead at (416) 822 5883 or http://www.medicalservicesintl.com/ or http://www.minerva-biotech.com/ .

NOTE: Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that may cause results to differ materially. Such risks, uncertainties and other factors include but are not limited to new economic conditions, risk in product development, market acceptance of new products and continuing product demand, level of competition and other factors described in Company reports and other filings with regulatory bodies.

First Call Analyst: FCMN Contact:

Medical Services International Inc.

CONTACT: Robert Talbot, +1-780-430-6363 or Bill Whitehead,+1-416-822-5883, both of Medical Services International Inc.

Web site: http://www.medicalservicesintl.com/http://www.minerva-biotech.com/

Source: PRNewswire-FirstCall

More News in this Category